Changing patterns in the use of slow acting antirheumatic drugs for the treatment of rheumatoid arthritis.
OBJECTIVE
To report on the changing use of slow acting antirheumatic drugs in the treatment of rheumatoid arthritis by contrasting prescribing patterns in 1990 and 1995.


METHODS
Data were extracted from the case notes of 103 outpatients with rheumatoid arthritis. Results were compared with those obtained in 1990 in a survey of 81 patients using identical methods.


RESULTS
There was a significant increase in the use of methotrexate between 1990 and 1995, and a marked decrease in the use of auranofin. A new feature was the use of drugs in combination. Methotrexate was the most effective agent and auranofin least effective (p = 0.02). The agent with the highest average toxicity score was D-penicillamine. The long term tolerability of methotrexate was superior, with a median time for remaining on therapy 6.4 times longer than that of the other slow acting antirheumatic drugs (p = 0.01).


CONCLUSIONS
Our results suggest that identified trends in the altered use of slow acting antirheumatic drugs for treatment of rheumatoid arthritis are rationally based on the increased use of the most effective agents and decreased use of those with greater toxicity and lesser efficacy.
Department of Pharmacology, School of Medical Sciences, University of Otago, Dunedin.
M W
MW
Horsfall
J P
JP
Shaw
J
J
Highton
P J
PJ
Cranch
D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000639:trends; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001310:Auranofin / Q000008:administration & dosage / Q000009:adverse effects; D015331:Cohort Studies; D003692:Delayed-Action Preparations; D004363:Drug Utilization / Q000639:trends; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009520:New Zealand; D012189:Retrospective Studies; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D003692:Delayed-Action Preparations; D001310:Auranofin; D008727:Methotrexate